AAV-Mediated PRPF31 Gene Delivery for Retinitis Pigmentosa
Solution Overview
Problem
Mutations in the Pre-mRNA Processing Factor 31 (PRPF31) gene cause non-syndromic retinitis pigmentosa (RP), an inherited retinal dystrophy, but the mechanisms and affected tissues are unclear.
Innovation Solution
The use of adeno-associated viral vectors (AAV), such as AAV2, to deliver a sequence encoding human PRPF31 operably linked to a promoter that drives expression in retinal pigment epithelial (RPE) cells, with the goal of treating retinitis pigmentosa or increasing PRPF31 expression in the eye.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If adeno-associated viral vectors are used to deliver PRPF31 encoding sequence to RPE cells, then PRPF31 expression is restored in retinal pigment epithelial cells, but the complexity of the treatment protocol increases
Solution Approach 1:
The patent uses adeno-associated viral vectors as intermediary carriers to deliver the PRPF31 encoding sequence to RPE cells. The viral vector acts as a mediator that facilitates gene transfer into the target cells, enabling restoration of PRPF31 expression without requiring direct cellular manipulation. This resolves the contradiction by providing a reliable delivery mechanism while maintaining procedural feasibility through established viral transduction protocols
2Length of moving object
If RPE-specific promoters are used to drive PRPF31 expression, then expression is targeted to retinal pigment epithelial cells, but the design complexity of the expression construct increases
Solution Approach 1:
The patent employs RPE-specific promoters (such as RPE65 or VMD2 promoters) to drive PRPF31 expression selectively in retinal pigment epithelial cells. This local quality approach ensures that the therapeutic gene is expressed only in the target cell type, providing tissue-specificity without requiring complex spatial control mechanisms. The promoter sequence itself encodes the targeting information, simplifying the overall construct design while achieving precise expression localization
Data Source
AI summary
The present invention relates to methods and compositions for gene therapy of retinitis pigmentosa related to mutations in pre-mRNA processing factor 31 (PRPF31).